Industry leaders and healthcare experts said the proposed US tariffs on imported generic medicines should push India's pharmaceutical sector to diversify export markets, boost innovation and strengthen resilient supply chains while ensuring affordable medicines remain accessible to patients worldwide
US President Donald Trump announced phased tariffs on imported generic medicines, keeping them at zero until 2028 before raising them to 100 and 200 per cent. The policy aims to boost domestic manufacturing and could significantly affect India's pharmaceutical exports
